查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495442

消化不良药物市场：按类型、药物类型、分销管道划分 - 全球预测 2024-2030

Dyspepsia Drug Market by Type (Functional Dyspepsia, Organic Dyspepsia), Drug Type (Acid Reducer, Antacids, Antibiotics), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

消化不良治疗市场规模预计2023年为85.8亿美元，预计2024年将达到90.1亿美元，2030年将达到121.8亿美元，复合年增长率为5.12%。

消化不良药物市场包括所有用于治疗慢性或復发性上腹部疼痛、不适、腹胀和噁心（俗称消化不良）的药物。由于饮食、压力、老化等原因，世界上消化不良的发病率不断增加，这大大增加了对有效治疗解决方案的需求。胃肠道药物治疗研究的改进导致了更有效、起效更快的药物的开发，改善了患者的治疗效果。加强医疗基础设施和提高人们对治疗选择的认识也推动了市场的成长。然而，长期使用某些消化不良药物（例如质子帮浦阻断剂（PPI））相关的潜在副作用可能会阻碍其使用并影响市场成长。开发新药需要大量投资，并且存在临床试验失败的风险，这对市场进入和技术创新造成了重大障碍。此外，人们对可以解决多种病症并提供综合治疗方法、提高患者依从性和治疗结果的联合治疗越来越感兴趣。遗传和分子谱分析的进步可能会带来更个人化的治疗方法，从而优化治疗效果并最大限度地减少副作用。

主要市场统计
基准年[2023] 85.8亿美元
预测年份 [2024] 90.1亿美元
预测年份 [2030] 121.8亿美元
复合年增长率（%） 5.12%

区域洞察

在美洲地区，製药和医疗保健产业随着消化不良治疗的持续创新和研究而不断发展。美洲市场的特点是严格监管，确保提供有效和安全的治疗方法。加拿大提供先进的医疗保健，我们对药物核准采取预防措施，确保投放市场的药物经过严格审查。欧洲国家受益于欧洲药品管理局 (EMA) 的全面监管，简化了医药品认证过程。生活方式的改变和老年人口的增加导致该地区消化不良治疗的需求不断增长。中东地区医疗保健支出的增加和对胃肠道疾病的认识不断提高，促进了市场的成长。非洲地区更注重可近性和可负担性，政府采取措施努力让更多人更容易获得治疗。亚太地区消化不良的盛行率显着增加，主要是由于饮食变化和压力水平增加。中国、日本和印度等国家正大力投资医疗基础设施和研究，以解决医疗保健问题。印度和中国人口众多，代表着多元化的市场，对胃肠道问题的非处方药和处方笺治疗的认识和需求不断增长。日本人口老化青睐高品质、精确配方的胃肠道疾病治疗，这是市场成长的重要动力。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在消化不良治疗药物市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对消化不良治疗市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该领域竞争性质的宝贵见解，包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对他们目前在消化不良治疗市场中的地位进行全面评估将有助于公司做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球消化不良盛行率飙升
      • 支持加速药品核准流程的政府政策
      • 投资改良药物输送和包装技术
    • 抑制因素
      • 产品召回与安全问题
    • 机会
      • 透过联合开发和公私合营进行扩张
      • 提高药物疗效的研发进展
    • 任务
      • 假药的可用性
  • 市场区隔分析
    • 类型：功能性消化不良的广泛发生和转向更个性化的药物
    • 药物类型：越来越多地使用质子帮浦阻断剂和H2受体阻断剂来治疗消化不良
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章消化不良治疗药物市场：依类型

  • 功能性消化不良
  • 器质性消化不良

第七章消化不良治疗药物市场（按类型）

  • 抑酸剂
  • 制酸剂
  • 抗生素
  • 抗惊厥药
  • 抗忧郁症
  • 西咪替丁
  • 法莫替丁
  • H2拮抗剂
  • 尼扎替丁
  • 消化促进剂
  • 质子帮浦抑制剂
  • Rabeprazole
  • 赞塔克

第八章消化不良治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美及南美消化不良药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太消化不良治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲/中东/非洲消化不良药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 突破性 FDA核准，Fathom Pharmaceuticals 宣布糜烂性胃食道逆流症治疗药物 VOQUEZNA
    • 剪切机-Smith推出法莫替丁口服混悬剂是美国学名药市场的策略性倡议。
    • Mark Sands Pharma非专利药法莫替丁锭获得美国FDA核准
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-5D693B46BAC4

[193 Pages Report] The Dyspepsia Drug Market size was estimated at USD 8.58 billion in 2023 and expected to reach USD 9.01 billion in 2024, at a CAGR 5.12% to reach USD 12.18 billion by 2030.

The dyspepsia drug market includes all pharmaceuticals used in the treatment of dyspepsia, commonly known as indigestion, identified by chronic or recurrent pain in the upper abdomen, a feeling of discomfort, bloating, and nausea, which may or may not be related to meals. Rising global incidences of dyspepsia, driven by dietary habits, stress, and the aging population, significantly contribute to the demand for effective treatment solutions. Improved research in gastrointestinal pharmacotherapy has led to the development of more effective and faster-acting drugs, enhancing patient outcomes. Enhanced healthcare infrastructure, along with growing awareness of treatment options among populations, boosts the market growth. However, potential adverse effects associated with long-term use of certain dyspepsia drugs, such as Proton-pump inhibitor (PPIs), can deter their usage and affect market growth. Significant investment required for new drug development and risk of failure in clinical trials are major barriers to entry and innovation in the market. Moreover, growing interest in exploring combination therapies that can address multiple symptoms or provide a comprehensive treatment regimen, thus improving patient adherence and outcomes. Advances in genetic and molecular profiling can lead to more personalized treatment approaches, optimizing therapeutic effectiveness and minimizing side effects.

KEY MARKET STATISTICS
Base Year [2023] USD 8.58 billion
Estimated Year [2024] USD 9.01 billion
Forecast Year [2030] USD 12.18 billion
CAGR (%) 5.12%

Regional Insights

In the Americas region, pharmaceutical and healthcare sectors are advancing with ongoing innovations and research in dyspepsia drugs. The Americas market is characterized by strong regulations, which ensure the availability of effective and safe treatments. Canada offers a sophisticated healthcare landscape with a more precautionary approach towards drug approval which ensures drugs entering the market are highly vetted. European countries benefit from collective regulations under the European Medicines Agency (EMA), which streamlines drug approval processes. Lifestyle changes and an increasing elderly population contribute to the growing need for dyspepsia drugs in the region. The Middle East region shows increasing healthcare expenditure and growing awareness about gastrointestinal diseases, contributing to the market growth. The African region is more focused on accessibility and affordability, with efforts aimed at making treatments available to a more significant portion of the population through governmental initiatives. The Asia Pacific region observed a significant surge in the prevalence of dyspepsia, primarily due to changes in dietary habits and increasing stress levels. Countries such as China, Japan, and India are heavily investing in healthcare infrastructure and research to address healthcare issues. With vast populations, India and China present a diverse market with increasing awareness and demand for over-the-counter and prescription treatments for gastrointestinal issues. Japan's aging population is a notable factor contributing to the market growth, observing a preference for high-quality and precisely formulated dyspepsia medications.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Dyspepsia Drug Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Surging prevalence of Dyspepsia worldwide
      • Government policies favoring faster drug approval processes
      • Investment in improved drug delivery and packaging technologies
    • Market Restraints
      • Product recall and safety concerns
    • Market Opportunities
      • Expansion through collaborative development and public-private partnerships
      • Advancements in research and development for enhanced drug efficacy
    • Market Challenges
      • Availability of the counterfeit drugs
  • Market Segmentation Analysis
    • Type: Wide occurrence of functional dyspepsia with the shift towards more personalized drugs
    • Drug Type: Growing utilization of proton pump inhibitors and H2 receptor blockers for dyspepsia treatment
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Dyspepsia Drug Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Dyspepsia Drug Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Breakthrough FDA Approval, Phathom Pharmaceuticals Unveils VOQUEZNA for Erosive GERD Treatment

Phathom Pharmaceuticals Inc., specializing in GI disease solutions, has received FDA approval for VOQUEZNA (vonoprazan) in both 10 mg and 20 mg tablets, introducing a significant advancement in the treatment of Erosive GERD for adults. This development provides a fresh treatment option for the roughly 20 million Americans suffering from this severe form of acid reflux, addressing a critical need unmet by existing therapies. [Published On: 2023-11-01]

Launch of Upsher-Smith's Famotidine for Oral Suspension, A Strategic Move in the U.S. Generic Drug Market

Upsher-Smith Laboratories, LLC, in collaboration with Appco Pharma LLC, has introduced Famotidine for Oral Suspension, USP to the U.S. market. Upsher-Smith, renowned for its commitment to quality and consistent supply, offers this FDA-approved medication to provide an alternative treatment for conditions addressed by famotidine. [Published On: 2023-08-16]

Marksans Pharma Secures USFDA Approval for Generic Famotidine Tablets

Marksans Pharma Ltd. has announced receiving the final approval from the U.S. Food and Drug Administration (USFDA) for its generic Famotidine tablets, used in treating acid indigestion and heartburn. The company intends to expand its over-the-counter gastrointestinal portfolio with this product, addressing a significant therapeutic need that emerged following the withdrawal of Ranitidine to better serve customers and fill a vital market gap in antacid therapies. [Published On: 2023-03-10]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Dyspepsia Drug Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Dyspepsia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Cadila Pharmaceuticals, Dr Reddy's Laboratories Ltd, Haleon PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Mankind Pharma, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Dyspepsia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Functional Dyspepsia
    • Organic Dyspepsia
  • Drug Type
    • Acid Reducer
    • Antacids
    • Antibiotics
    • Anticonvulsant
    • Antidepressants
    • Cimetidine
    • Famotidine
    • H2 Antagonist
    • Nizatidine
    • Prokinetic agent
    • Proton-pump Inhibitor
    • Rabeprazole
    • Zantac
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of Dyspepsia worldwide
      • 5.1.1.2. Government policies favoring faster drug approval processes
      • 5.1.1.3. Investment in improved drug delivery and packaging technologies
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall and safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion through collaborative development and public-private partnerships
      • 5.1.3.2. Advancements in research and development for enhanced drug efficacy
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of the counterfeit drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Wide occurrence of functional dyspepsia with the shift towards more personalized drugs
    • 5.2.2. Drug Type: Growing utilization of proton pump inhibitors and H2 receptor blockers for dyspepsia treatment
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Dyspepsia Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Functional Dyspepsia
  • 6.3. Organic Dyspepsia

7. Dyspepsia Drug Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Acid Reducer
  • 7.3. Antacids
  • 7.4. Antibiotics
  • 7.5. Anticonvulsant
  • 7.6. Antidepressants
  • 7.7. Cimetidine
  • 7.8. Famotidine
  • 7.9. H2 Antagonist
  • 7.10. Nizatidine
  • 7.11. Prokinetic agent
  • 7.12. Proton-pump Inhibitor
  • 7.13. Rabeprazole
  • 7.14. Zantac

8. Dyspepsia Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Dyspepsia Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Dyspepsia Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Dyspepsia Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Breakthrough FDA Approval, Phathom Pharmaceuticals Unveils VOQUEZNA for Erosive GERD Treatment
    • 12.3.2. Launch of Upsher-Smith's Famotidine for Oral Suspension, A Strategic Move in the U.S. Generic Drug Market
    • 12.3.3. Marksans Pharma Secures USFDA Approval for Generic Famotidine Tablets
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DYSPEPSIA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. DYSPEPSIA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DYSPEPSIA DRUG MARKET DYNAMICS
  • FIGURE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DYSPEPSIA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORGANIC DYSPEPSIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORGANIC DYSPEPSIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ACID REDUCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ACID REDUCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CIMETIDINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FAMOTIDINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY NIZATIDINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETIC AGENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETIC AGENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON-PUMP INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON-PUMP INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ZANTAC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ZANTAC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. CHINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. CHINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. INDIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. INDIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 120. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 121. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 132. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 177. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. ITALY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. ITALY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. POLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. POLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 242. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 243. QATAR DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. QATAR DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 278. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 279. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 290. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 291. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 302. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 303. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 304. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023